Table 1.
Patient demographics of development and validation cohorts
| Variable | Cohort 1 | Cohort 2 | P | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All | No csPCa | Yes csPCa | P1 | All | No csPCa | Yes csPCa | P2 | ||
| Case, n (%) | 847 | 542 (63.99) | 305 (36.01) | 208 | 110 (52.9) | 98 (47.1) | |||
| Age, years (mean ± SD) | 69.29 ± 8.45 | 67.51 ± 8.1 | 72.44 ± 8.1 | < .001 | 70.28 ± 7.96 | 68.73 ± 7.61 | 72.02 ± 8.02 | 0.003 | 0.113 |
| TPSA, ng/ml, M (IQR) | 14.6 (8.6–32.0) | 11.8 (7.7–18.2) | 39.6 (14.7–104.3) | < .001 | 14.2 (9.3–35.7) | 11.4 (7.6–20.2) | 27.9 (12.6–79.3) | < .001 | 0.410 |
| F/T, %, M (IQR) | 13.8 (8.8–20.0) | 14.5 (8.4–20.5) | 12.6 (7.8–18.4) | 0.064 | 14.3 (9.8–19.6) | 15.6 (12.1–21.0) | 11.7 (8.6–17.5) | 0.002 | 0.224 |
| PV, ml, M (IQR) | 54.1 (38.5–82.4) | 60.7 (43.5–89.9) | 45.1 (30.9–63.9) | < .001 | 52.5 (36.9–79.1) | 73.5 (49.1–94.6) | 44.1 (32.9–62.4) | < .001 | 0.661 |
| PSAD, ng/ml/ml, M (IQR) | 0.26 (0.14–0.71) | 0.19 (0.10–0.30) | 0.88 (0.40–2.30) | < .001 | 0.27 (0.15–0.82) | 0.16 (0.11–0.25) | 0.68 (0.33–2.06) | < .001 | 0.342 |
| PSAD < 0.15, n (%) | 219 (25.86) | 200 (36.90) | 19 (6.23) | 50 (24.04) | 45 (40.91) | 5 (5.10) | |||
| 0.30 > PSAD ≥ 0.15, n (%) | 256 (30.22) | 214 (39.48) | 42 (13.77) | 56 (26.92) | 39 (35.45) | 17 (17.35) | |||
| 0.45 > PSAD ≥ 0.30, n (%) | 96 (11.33) | 58 (10.70) | 38 (12.46) | 19 (9.13) | 8 (7.27) | 11 (11.22) | |||
| PSAD ≥ 0.45, n (%) | 276 (32.59) | 70 (12.92) | 206 (67.54) | 83 (39.90) | 18 (16.36) | 65 (66.33) | |||
| PI-RADS v2.1 grade, n (%) | < .001 | < .001 | < .001 | ||||||
| 1–2 | 247 (29.16) | 240 (44.28) | 7 (2.30) | 71 (34.13) | 64 (58.18) | 7 (7.14) | |||
| 3 | 241 (28.45) | 212 (39.11) | 29 (9.51) | 39 (18.75) | 30 (27.27) | 9 (9.18) | |||
| 4–5 | 359 (42.38) | 90 (16.61) | 269 (88.20) | 98 (47.12) | 16 (14.55) | 82 (83.67) | |||
| Biopsy results, n (%) | < .001 | < .001 | 0.093 | ||||||
| No cancer | 481 (56.79) | 104 (50.00) | |||||||
| Gleason score < 7 | 61 (7.20) | 6 (2.88) | |||||||
| Gleason score 7 | 89 (10.51) | 29 (13.94) | |||||||
| Gleason score 8 | 83 (9.80) | 23 (11.06) | |||||||
| Gleason score 9 | 92 (10.86) | 31 (14.90) | |||||||
| Gleason score 10 | 41 (4.84) | 15 (7.21) | |||||||
TPSA Total PSA, F/T Proportion of free PSA, PV Prostate volume, PSAD PSA density